NCT06947291

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors With MET Overexpression and/or Amplification

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 350 (estimated)
• Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.

Conditions

• Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Interventions

Type	Name	Description
DRUG	Glumetinib Tablets	glumetinib once daily once daily under fasting conditions in each 21-day treatment cycle.
DRUG	Docetaxel for Injection (Albumin-bound)	Docetaxel for Injection (Albumin-bound) by intravenous injection in each 21-day treatment cycle.

Timeline

• Start date: 2025-06-04
• Primary completion: 2027-04-30
• Completion: 2027-10-30
• First posted: 2025-04-27
• Last updated: 2025-09-08

Locations

1 site across 1 country: China